Recruiting
Phase 4

Tirzepatide

Sponsor:

University of North Carolina, Chapel Hill

Code:

NCT07756359

Conditions

Pouch, Ileal

Pouches, Ileoanal

Bowel Diseases, Inflammatory

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Tirzepatide

Loperamide

Diphenoxylate/Atropine

Study Details

Brief summary:

The goal of this clinical trial is to learn if Tirzepatide (Zepbound) can decrease bowel frequency in patients that have an ileal-pouch anal anastomosis (IPAA or pouch) better than standard of care anti-diarrheal therapy.

The main question it aims to answer is:

Does Tirzepatide reduce bowel frequency better than standard of care anti-diarrheal therapy in patients that have a pouch

Participants will:

Visit the clinic 5 times, answer questions about symptoms daily, be assigned to take the study product as instructed and provide a stool sample 4 times.

Conditions

Pouch, Ileal

Pouches, Ileoanal

Bowel Diseases, Inflammatory

Study ID

NCT07756359

Start date

Jan 4, 2027

Status verified date

Nov, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Informed consent will be obtained before any study-related procedures
  • Age > 18 and <80 years
  • Patients with an IPAA and bowel frequency > 8 bowel movements in 24 hours on at least 4 of 7 days/week (and/or an average of >8 bowel movements in the 7 days preceding enrollment)

  • Patients must have demonstrated high bowel frequency despite adequate therapy for high bowel frequency with loperamide 2 mg orally every 6 hours as needed (at least 3 doses daily) and/or diphenoxylate/atropine 2 mg orally every 6 hours as needed (at least 3 doses daily) or proven intolerance to these anti-diarrheal medications.
  • Among patients with inflammatory conditions of the pouch, high bowel frequency must be demonstrated despite adequate therapy for intermittent pouchitis, chronic pouchitis, or Crohn's like disease of the pouch. Adequate therapy is required to ensure significant pouch inflammation is not a driver of high bowel frequency (described in Exclusion Criteria).
  • Participants with a proven history of ulcerative colitis and history of 1,2, modified -2 or 3 stage IPAA and ileostomy takedown
  • Ability to access internet for electronic database entry

Exclusion Criteria:

  • Prior exposure to tirzepatide or other GLP-1RA
  • BMI <20 at the time of study screening
  • Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2
  • Known hypersensitivity to tirzepatide or its metabolites
  • Significant pouch inflammation defined as an endoscopic pouch disease activity index (PDAI ) ≥ 4
  • Known stricture of the ileo-anal anastomosis or afferent limb stricture
  • New onset of high bowel frequency in the setting of acute pouchitis
  • Final stage of IPAA surgery < 6 months prior to enrollment
  • Current infection with Clostridioides difficile
  • Known HIV or active Hepatitis B/C
  • Clinically significant liver disease (Primary Sclerosing Cholangitis with LFT's <1.5 upper limit of normal can be included)
  • Severe hepatic impairment, defined as Child-Pugh Class C
  • Known clinically significant chronic nausea and/or vomiting in the past
  • Known diagnosis of type 1 or type 2 diabetes
  • Known decreased kidney function with a glomerular filtration rate <30 ml/min/1.732
  • History of malignancy, except for basal cell carcinoma, non-metastatic squamous cell carcinoma of the skin, or prior malignancy with curative therapy completed at least 5 years prior to screening and no recurrence.
  • New York Heart Association class 3 or greater heart failure or recent (within 6 months) cardiovascular event
  • Prior history of pancreatitis
  • Clinically significant laboratory results at screening or baseline, as judged by the Investigator from local testing.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
  • Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days before screening.
  • Any disorder, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol.

Study Design

Enrollment

20 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Tirzepatide

Treatment will start at 2.5 mg once weekly. After 4 weeks, the dose will be increased to 5 mg once weekly. After another 4 weeks, the dose will be increased to 7.5 mg once weekly for 4 weeks.

active comparator: Optimized Standard of Care anti-diarrheal therapy

Optimized regimen of loperamide 2 mg orally every 6 hours as needed for increased frequency or diphenoxylate/atropine can be given 2 mg orally every 6 hours. When using either or both therapies in combination the participant should not exceed a maximum dose of 16 mg orally within 24 hours. For participants with continued or worsening high bowel frequency for >2 weeks, transition to active therapy with tirzepatide will be offered at week 4. Tirzepatide treatment would begin as 2.5 mg once weekly. After 4 weeks, the dose will be increased to 5 mg once weekly. After another 4 weeks, the dose will be increased to 7.5 mg once weekly for 4 weeks.

Interventions

Tirzepatide

Tirzepatide will be administered subcutaneously

Loperamide

2 mg orally every 6 hours as needed

Diphenoxylate/Atropine

2 mg orally every 6 hours

Primary outcome measure

  • Proportion of patients achieving a decrease of the average daily bowel frequency by 30% at week 12 (Week 16 if applicable) [ Time Frame: Week 12 (Week 16 if applicable) ]

Central Contacts and Locations

Central contacts

Locations

University of North Carolina

Recruiting

Chapel Hill, North Carolina, United States, 27599

Contacts

Principal Investigator:

Edward Barnes, MD, MPH

More Information

Sponsor

University of North Carolina, Chapel Hill

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • High Bowel Frequency
  • IPAA
  • ileal pouch-anal anastomosis

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by University of North Carolina, Chapel Hill on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.